摘要
目的：探讨miR-141、miR-145作为非小细胞肺癌（non-small cell lung cancer,NSCLC）生物标志物的诊断价值。方法：采用实时荧光定量PCR技术检测80例正常人和80例非小细胞肺癌患者血清中miR-141、miR-145的表达量,分析miR-141、miR-145的表达与非小细胞肺癌临床病理参数的关系,并绘制ROC曲线分析其诊断非小细胞肺癌的价值。结果：非小细胞肺癌患者miR-141、miR-145表达与对照组比较有统计学差异（P〈0.05）,二者联合的诊断效能分别为：灵敏度92%（95%CI：0.86~0.96）,特异度83%,（95%CI：0.73~0.88）,阳性预测值（PPV）86%,阴性预测值（NPV）92%。结论：血清中miR-141、miR-145测定的诊断性能较高,可以作为非小细胞肺癌的潜在的诊断标志物。
Objective： To evaluate the value of expression of serum miR-141 and miR-145 in the diagnosis of non-small cell lung cancer（ NSCLC）. Methods： Serum miR-141 and miR-145 level were measured by real time-PCR. 160 samples were divided into two sets 80 patients with NSCLC,80 healthy volunteers. sensitivity,specificity,positive predictive value（ PPV） and negative predictive value（ NPV）. Results： In training set,the expression of miR-141 and miR-145 were significant different compared to the control group. In the test set,the diagnostic values of miR-141 and miR-145 were as follow： sensitivity 92%（ 95% CI： 0. 86 ~ 0. 96）,specificity 83%（ 95% CI： 0. 73 ~0. 88）,PPV86% and NPV 92%. Conclusion： Serum miR-141 and miR-145 can be used as early biomarkers for NSCLC.
出处
《现代肿瘤医学》
CAS
2016年第4期585-588,共4页
Journal of Modern Oncology
基金
陕西省科技攻关资助项目(编号:2012K13-02)
